Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01667419 · ClinicalTrials.gov registry record · Phase 3
A Study of Vemurafenib Adjuvant Therapy in Participants With Surgically Resected Cutaneous BRAF-Mutant Melanoma
A Phase 3 study of Melanoma, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 3
- Development phase
- 498
- Enrollment target
- 20
- Study locations
NCT01667419: Completed Phase 3 study of Melanoma, sponsored by Hoffmann-La Roche.
NCT01667419 is a Phase 3 study of Melanoma that has completed, run by Hoffmann-La Roche. The registered enrollment target is 498 participants, below the 705-participant average among 266 other Melanoma trials with a reported enrollment target (29% lower). The trial reports 20 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01667419, a Phase 3 study of Melanoma, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 498 participants
- Enrollment target
- 20
- Study locations
Study Summary
This multicenter, randomized, double-blind, placebo-controlled study will evaluate the efficacy and safety of vemurafenib in participants with completely resected, cutaneous BRAF mutation-positive melanoma at high risk for recurrence. Participants will be enrolled in two separate cohorts: Cohort 1 will include participants with completely resected Stage IIC, IIIA (participants with one or more nodal metastasis greater than \[\>\] 1 millimeter \[mm\] in diameter), or IIIB cutaneous melanoma, as defined by the American Joint Committee on Cancer (AJCC) Classification, Version 7; Cohort 2 will include participants with Stage IIIC cutaneous melanoma, as defined by this classification scheme. Within each cohort, participants will be randomized (1:1 ratio) to receive vemurafenib or matching placebo over a 52-week period.
Primary Outcome
DFS was defined as the time from randomization until the date of the first local, regional, or distant melanoma recurrence, occurrence of new primary melanoma, or death from any cause.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Vemurafenib
Study Locations (20)
California
- UCLA Department of Medicine; Division of Hematology / Oncology - California City
- Kaiser Permanente - Hayward - Hayward
- UCLA Hematology Oncology - Irvine - Irvine
- UCSD Moores Cancer Center - La Jolla
- The Angeles Clinic and Research Institute - W LA Office - Los Angeles
- Cancer Center Of Santa Barbara; Network Clinical Research Specialist - Los Angeles
- TRIO-US Network Administration; Network Clinical Research Specialist - Los Angeles
- Kaiser Foundation Hospital - Oakland (W. MacArthur) - Oakland
- Kaiser Permanente - Oakland - Oakland
- UCLA Healthcare/Pasadena Oncology - Pasadena
- Kaiser Permanente - Roseville - Roseville
- Kaiser Permanente Sacramento Medical Center - Sacramento
- Kaiser Permanente - San Francisco
- K. Permanente - San Jose - San Jose
- Coastal Integrative Cancer Care - San Luis Obispo
- Kaiser Permanente - Santa Clara - Santa Clara
- Kaiser Permanente - South San Francisco - South San Francisco
- Stanford University School of Medicine; Stanford Hospital Pharmacy - Stanford
- UCLA Cancer Center Hema/Oncol - Valencia
Alabama
- University of Alabama at Birmingham - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 498 participants |
| Start Date | 2012-09-24 |
| Est. Completion | 2018-07-13 |
| Phase | Phase 3 |
What the finished NCT01667419 record still lists
NCT01667419 is an interventional study that assigns participants to a tested intervention. The registered 498 participants enrollment target is mid-sized for trials with a published cap, below the 705-participant average among 266 other Melanoma trials with a reported enrollment target (29% lower).
The record links to 1 condition, with Melanoma appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01667419 names 20 study sites across 2 states, led by California, Alabama.
Frequently Asked Questions
What is clinical trial NCT01667419 about?
NCT01667419 is a clinical study titled "A Study of Vemurafenib Adjuvant Therapy in Participants With Surgically Resected Cutaneous BRAF-Mutant Melanoma". This multicenter, randomized, double-blind, placebo-controlled study will evaluate the efficacy and safety of vemurafenib in participants with completely resected, cutaneous BRAF mutation-positive melanoma at high risk for recurrence. Participants will be enrolled in two separate cohorts: Cohort 1 w...
What is the current status of trial NCT01667419?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 498 participants. The study started on 2012-09-24. Estimated completion is 2018-07-13.
What conditions does trial NCT01667419 study?
This clinical trial studies the following conditions: Melanoma.
What interventions are being tested in trial NCT01667419?
The interventions under investigation include: Placebo (DRUG), Vemurafenib (DRUG).
Who is sponsoring clinical trial NCT01667419?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01667419 being conducted?
This trial has 20 study locations across Alabama, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01667419's enrollment target sits among peer trials
498 39th of 266 higher than 228 of 266 other Melanoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Melanoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
RECRUITING · Phase 3
-
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
RECRUITING · Phase 3
-
Randomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation Therapy
ACTIVE NOT RECRUITING · Phase 3
-
A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)
ACTIVE NOT RECRUITING · Phase 3
-
A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma
ACTIVE NOT RECRUITING · Phase 3
-
Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04137900 · 499 participants · Phase 1
Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies
- NCT06733480 · 499 participants · NA
Innovating Physical Therapy: A Pilot Study on Band Connect's Impact on Compliance, Satisfaction, and Revenue
- NCT03175224 · 497 participants · Phase 2
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
- NCT05301816 · 497 participants · NA
PDN Post Market, Multicenter, Prospective, Global Clinical Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI